Shares of Heat Biologics (NASDAQ:HTBX) saw unusually-strong trading volume on Wednesday . Approximately 8,848,146 shares were traded during mid-day trading, an increase of 607% from the previous session’s volume of 1,252,234 shares.The stock last traded at $2.06 and had previously closed at $1.99.
Separately, ValuEngine cut Heat Biologics from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd.
Heat Biologics (NASDAQ:HTBX) last issued its earnings results on Tuesday, May 15th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by ($0.05). Heat Biologics had a negative return on equity of 182.19% and a negative net margin of 543.30%. The firm had revenue of $0.75 million during the quarter. research analysts expect that Heat Biologics will post -7.1 EPS for the current fiscal year.
About Heat Biologics
Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.
Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.